Form 4: Altimmune CBO Vests RSUs, Sells Shares for Tax

Altimmune's Chief Business Officer, Raymond M. Jordt, acquired 14,600 shares through RSU vesting and sold 3,855 shares to cover tax obligations.

Summary

• Raymond M. Jordt, Chief Business Officer of Altimmune, Inc., acquired 14,600 shares of common stock on January 25, 2026, through the vesting of Restricted Stock Units (RSUs).
• Concurrently, 3,855 shares were disposed of at a price of $5.50 per share to cover tax liabilities associated with the RSU vesting.
• Following these transactions, Jordt beneficially owns 53,915 shares of common stock and 29,200 unvested Restricted Stock Units.
• The RSUs are part of a grant that vests in substantially equal annual installments over four years, commencing from January 25, 2024.

Sentiment

Score: 5

Explanation: Neutral. This is a routine insider transaction related to compensation and tax, not indicative of positive or negative company performance or strategic shifts.

Positives

• The vesting of RSUs indicates continued service by a key executive, aligning management's interests with long-term shareholder value.
• The acquisition of 14,600 shares of common stock increases the executive's direct equity stake in the company.

Negatives

• The sale of 3,855 shares, while for tax purposes, results in a reduction of the executive's direct shareholding.

Future Outlook

The remaining 29,200 Restricted Stock Units held by the Chief Business Officer are expected to vest in two substantially equal annual installments of 14,600 RSUs each, on January 25, 2027, and January 25, 2028, contingent on continued service.

Industry Context

This filing is a routine insider transaction report, common across all industries, reflecting executive compensation and tax management. It does not provide specific insights into Altimmune's operational performance or broader industry trends.

Comparison to Industry Standards

• This is a standard insider transaction (Form 4) related to equity compensation vesting and tax withholding, which is a common practice for executives across publicly traded companies. There are no specific comparable companies, projects, or results to list as this is a personal transaction report.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting is offset by executive alignment. The tax-related sale is a routine event and does not signal a change in confidence.
• Employees: Reflects standard executive compensation practices.

Next Steps

• Continued vesting of the remaining 29,200 Restricted Stock Units in two annual installments of 14,600 RSUs each on January 25, 2027, and January 25, 2028, subject to the reporting person's continued service.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are standard components of executive compensation and do not provide new fundamental information about Altimmune's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider filing.

Keywords

Altimmune, ALT, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Raymond M. Jordt, Chief Business Officer, Equity Compensation, Stock Sale